S1475 Burden and Impact of Fatigue on Patients with Crohn’s Disease and Ulcerative Colitis in the United States and Europe: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Introduction: Fatigue is a common yet debilitating symptom with multifactorial etiology (e.g., inflammation, sleep disturbances) which significantly impacts quality of life of patients (pts) with inflammatory bowel disease (IBD). The Communicating Needs and Features of IBD Experiences (CONFIDE) study explored the burden and impact of Crohn’s disease/ulcerative colitis (CD/UC)-related symptoms on pts’ lives in the United States (US), Europe (EU5: France, Germany, Italy, Spain, and UK) and Japan. Methods: An online, quantitative, cross-sectional survey was conducted in pts with moderate-to-severe CD/UC. Moderate-to-severe CD/UC were defined using criteria based on previous treatment, steroid use, and/or hospitalization. Patients were asked about the impact of CD/UC-related fatigue on their work/school, social, physical, and sexual activities. Descriptive statistics were used to summarize data from US and EU5. Results: Overall, 215 US (men [M]=55%, mean age=41 years) and 547 EU5 (M=55%, mean age=38 years) pts with CD, and 200 US (M=62%, mean age=40 years) and 556 EU5 (M=57%, mean age=39 years) pts with UC completed the survey (Table 1). Overall, 36% US and 34% EU5 pts with CD, and 28% US and 21% EU5 pts with UC reported currently experiencing fatigue (in the past month). A total of 46% US and 45% EU5 pts with CD, and 40% US and 31% EU5 pts with UC reported ever experiencing fatigue. Similar results were observed in pts receiving advanced therapies (Current: CD, US: 36%, EU5: 34%; UC, US: 26%, EU5: 20%; Ever: CD, US: 47%, EU5: 46%; UC, US: 36%, EU5: 29%). In past 3 months, 19–24% and 15–24% pts with CD and UC, respectively reported declining participation in work/school, social activities, and sports/physical exercise due to fatigue (Figure 1A). Among pts with CD/UC who ever experienced fatigue, most reported that fatigue impacted their work/school-related activities (CD, US:74%, EU5:71%; UC, US:70%, EU5:74%). Of these, >40% pts worked for fewer hours and >30% stopped working for the day sooner than planned due to CD/UC-related fatigue (Figure 1B). Among pts who reported reduced sexual activity in past 3 months (CD, US:69%, EU5:56%; UC, US:63%, EU5:53%), 38% US and 30% EU5 pts with CD, and 29% US and 18% EU5 pts with UC attributed it to CD/UC-related fatigue. Conclusion: Fatigue is a prevalent symptom of moderate-to-severe CD/UC which adversely affects pts’ work/school, social, physical, and sexual activities. This underscores the need to develop fatigue-related treatment strategies in CD and UC.Figure 1.: Impact of fatigue on health-related quality of life of patients with CD/UC (A) Patients who declined participation in work/school, social activities, and sports/physical exercise in the past 3 months due to CD/UC-related fatigue (B) Impact of CD/UC-related fatigue on work/school among patients who reported ever experiencing fatigue. CD, Crohn's disease; UC, Ulcerative colitis; US, United States. Table 1. - Demographics and characteristics of patients with CD and UC Patients with CD Patients with UC US (N=215) Europe (N=547) US (N=200) Europe (N=556) Mean age, years (SD) 40.9 (11.4) 38.0 (9.7) 40.4 (10.8) 38.9 (8.8) Male, n (%) 118 (54.9) 303 (55.4) 123 (61.5) 319 (57.4) Ethnicity, n (%) White 175 (81.4) 515 (94.1) 155 (77.5) 518 (93.2) Hispanic/Latino 21 (9.8) 1 (0.2) 23 (11.5) 3 (0.5) African American 12 (5.6) 0 18 (9.0) 0 Other* 6 (2.8) 31 (5.7) 4 (2.0) 35 (6.3) Time since diagnosis of CD/UC, (mean years [SD]) 8.7 (8.6) 9.2 (8.5) 7.9 (8.6) 7.9 (7.5) Advanced therapy, n (%)^ 125 (58.1) 347 (63.4) 153 (76.5) 301 (54.1) *Other races included Asian-Indian subcontinent, Asian-other, Japanese, Korean, Middle Eastern, Afro-Caribbean, Native American, Mixed race, South-East Asian, and other. ^Advanced therapy defined as biologic therapy, biosimilar, or Janus kinase inhibitor. CD, Crohn’s disease; SD, standard deviation; UC, ulcerative colitis; US, United States.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,002 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle